Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Acquired hemophagocytic lymphohistiocytosis (HLH) associated with malignant disease, also known as malignancy-associated hemophagocytic syndrome (MAHS), is a severe, life-threatening hyperinflammatory condition that occurs secondary to an underlying malignancy. It is classified under secondary (acquired) HLH, distinguishing it from the familial (primary) genetic forms. In this condition, the immune system becomes pathologically overactivated, leading to uncontrolled proliferation and activation of macrophages and T lymphocytes that infiltrate multiple organs and engulf blood cells (hemophagocytosis). The malignancies most commonly associated with this form of HLH are hematologic cancers, particularly lymphomas (especially T-cell and NK-cell lymphomas), leukemias, and less frequently solid tumors. The disease affects multiple body systems including the hematopoietic system, liver, spleen, central nervous system, and bone marrow. Key clinical features include persistent high fever, hepatosplenomegaly (enlarged liver and spleen), cytopenias (low blood cell counts affecting red cells, white cells, and platelets), hyperferritinemia (markedly elevated ferritin levels), hypertriglyceridemia, hypofibrinogenemia, and evidence of hemophagocytosis on bone marrow or tissue biopsy. Patients may also develop liver dysfunction, coagulopathy, and multi-organ failure. Neurological involvement can include seizures, altered consciousness, and meningeal signs. Treatment requires addressing both the hyperinflammatory HLH syndrome and the underlying malignancy. Initial management typically follows HLH-directed protocols, which may include corticosteroids, etoposide, cyclosporine A, and intrathecal therapy for central nervous system involvement, based on the HLH-94 or HLH-2004 protocols. Definitive treatment depends on achieving remission of the underlying cancer through appropriate chemotherapy, immunotherapy, or in some cases hematopoietic stem cell transplantation. The prognosis is generally poor, particularly when associated with aggressive lymphomas, and early recognition and treatment are critical for improving outcomes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Acquired hemophagocytic lymphohistiocytosis associated with malignant disease